Vaxil Bio Ltd.

As of June 30, 2026, Vaxil Bio Ltd. carries a market capitalization of 717,123.60, placing it among publicly traded companies globally. Its enterprise value stands at 253,123.60, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Vaxil Bio Ltd. has 3.98M shares outstanding.

As of June 30, 2026, Vaxil Bio Ltd. trades at a trailing price-to-earnings ratio of 1.74.

As of June 30, 2026, Vaxil Bio Ltd. maintains a current ratio of 17.97, meaning it holds 18.0x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Vaxil Bio Ltd. posted a return on equity (ROE) of 40.21, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) is negative at -27.06, so the business is destroying capital rather than earning a return above its cost of capital. Return on assets (ROA) stands at 39.46, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 40.21, useful for judging operating efficiency across full business cycles.

As of the close on October 22, 2026, Vaxil Bio Ltd.'s stock has declined approximately 31.58% over the past 52 weeks. The 50-day moving average sits at 0.17, while the 200-day moving average is 0.30.

Over the twelve months ended June 30, 2026, Vaxil Bio Ltd. generated - - in revenue and converted that into 379,000.00 in net income, yielding earnings per share of 0.10. EBITDA reached -255,000.00, while operating income came in at -255,000.00.

These figures are as of June 30, 2026. Total book value stands at 1.19M, with working capital of 509,000.00 providing operational flexibility.

Vaxil Bio Ltd. produced -266,000.00 in operating cash flow over the twelve months ended June 30, 2026.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -40.23: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow.

Vaxil Bio Ltd.'s most recent stock split took place on May 20, 2025 with a 50:1 split ratio.

As of June 30, 2026, Vaxil Bio Ltd. has an Altman Z-Score of -7.79, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.